CR20150386A - Composiciones de nanoparticulas de albumina y paclitaxel - Google Patents
Composiciones de nanoparticulas de albumina y paclitaxelInfo
- Publication number
- CR20150386A CR20150386A CR20150386A CR20150386A CR20150386A CR 20150386 A CR20150386 A CR 20150386A CR 20150386 A CR20150386 A CR 20150386A CR 20150386 A CR20150386 A CR 20150386A CR 20150386 A CR20150386 A CR 20150386A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- albumin
- paclitaxel nanoparticles
- paclitaxel
- nanoparticles
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 3
- 108010088751 Albumins Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 229930012538 Paclitaxel Natural products 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 229960001592 paclitaxel Drugs 0.000 title abstract 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261747123P | 2012-12-28 | 2012-12-28 | |
| US13/794,705 US20140186447A1 (en) | 2012-12-28 | 2013-03-11 | Nanoparticle compositions of albumin and paclitaxel |
| PCT/US2013/076630 WO2014105644A1 (en) | 2012-12-28 | 2013-12-19 | Nanoparticle compositions of albumin and paclitaxel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150386A true CR20150386A (es) | 2015-10-07 |
Family
ID=51017455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150386A CR20150386A (es) | 2012-12-28 | 2015-07-22 | Composiciones de nanoparticulas de albumina y paclitaxel |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20140186447A1 (OSRAM) |
| EP (1) | EP2938340A4 (OSRAM) |
| JP (2) | JP2016504362A (OSRAM) |
| KR (1) | KR20150100903A (OSRAM) |
| CN (1) | CN105007912A (OSRAM) |
| AU (1) | AU2013370955B2 (OSRAM) |
| BR (1) | BR112015015319A2 (OSRAM) |
| CA (1) | CA2896288A1 (OSRAM) |
| CR (1) | CR20150386A (OSRAM) |
| HK (1) | HK1216611A1 (OSRAM) |
| IL (1) | IL239593A0 (OSRAM) |
| MX (1) | MX2015008361A (OSRAM) |
| NI (1) | NI201500090A (OSRAM) |
| NZ (1) | NZ630912A (OSRAM) |
| PH (1) | PH12015501486B1 (OSRAM) |
| RU (1) | RU2663687C2 (OSRAM) |
| SG (1) | SG11201505111TA (OSRAM) |
| WO (1) | WO2014105644A1 (OSRAM) |
| ZA (1) | ZA201504762B (OSRAM) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1585548T (lt) | 2002-12-09 | 2018-09-25 | Abraxis Bioscience, Llc | Farmakologinių agentų kompozicijos ir įvedimo būdai |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| PT1931321T (pt) | 2005-08-31 | 2019-05-14 | Abraxis Bioscience Llc | Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos |
| ES2700074T3 (es) | 2006-12-14 | 2019-02-13 | Abraxis Bioscience Llc | Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano |
| ES2435452T3 (es) * | 2007-06-01 | 2013-12-19 | Abraxis Bioscience, Llc | Métodos y composiciones para tratar un cáncer recurrente |
| RS59896B1 (sr) | 2009-04-15 | 2020-03-31 | Abraxis Bioscience Llc | Kompozicije nanočestica bez priona i postupci povezani sa njima |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| KR102108959B1 (ko) | 2011-04-28 | 2020-05-11 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| AU2012253571A1 (en) | 2011-05-09 | 2014-01-09 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| WO2013090634A1 (en) | 2011-12-14 | 2013-06-20 | Abraxis Bioscience, Llc | Use of polymeric excipients for lyophilization or freezing of particles |
| US10413606B2 (en) | 2012-10-01 | 2019-09-17 | Mayo Foundation For Medical Education And Research | Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| NZ630213A (en) | 2013-03-14 | 2017-05-26 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| CN105407878A (zh) | 2013-05-30 | 2016-03-16 | 纳米生物技术公司 | 药物组合物、制备及其用途 |
| CN113318239B (zh) | 2014-06-13 | 2025-05-30 | 梅约医药教育及研究基金会 | 治疗淋巴瘤 |
| KR20210125603A (ko) | 2014-06-16 | 2021-10-18 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 골수종의 치료 |
| CN104224750A (zh) * | 2014-09-17 | 2014-12-24 | 四川大学 | 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法 |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| JP6836510B2 (ja) | 2014-11-25 | 2021-03-03 | キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ | 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用 |
| US10765632B2 (en) | 2014-11-25 | 2020-09-08 | Curadigm Sas | Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis |
| TW201628610A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
| DK3229843T3 (da) * | 2014-11-25 | 2020-03-09 | Curadigm Sas | Farmaceutisk sammensætning, præparat og anvendelser deraf |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA201792560A1 (ru) | 2015-05-28 | 2018-06-29 | Нанобиотикс | Наночастицы для применения в качестве терапевтической вакцины |
| CN116473964A (zh) | 2015-06-29 | 2023-07-25 | 阿布拉科斯生物科学有限公司 | 治疗上皮样细胞肿瘤的方法 |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| US11351254B2 (en) * | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| RU2019109211A (ru) | 2016-09-01 | 2020-10-01 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака |
| EP3510048A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Methods of treating pd-l1 expressing cancer |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2018048958A1 (en) | 2016-09-06 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| CN106420665B (zh) * | 2016-10-28 | 2019-04-16 | 浙江省林业科学研究院 | 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法 |
| BR112020005814A2 (pt) | 2017-10-03 | 2020-09-24 | Crititech, Inc. | administração local de partículas antineoplásicas em combinação com administração sistêmica de agentes imunoterapêuticos para o tratamento de câncer |
| RU2020134124A (ru) | 2018-03-20 | 2022-04-20 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ |
| US20220401374A1 (en) * | 2019-09-13 | 2022-12-22 | Purdue Research Foundation | Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules |
| CA3158764A1 (en) * | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| BR112022009018A2 (pt) * | 2019-11-11 | 2022-10-11 | Abraxis Bioscience Llc | Biomarcadores para composições de nanopartícula |
| WO2021158937A1 (en) * | 2020-02-05 | 2021-08-12 | The Johns Hopkins University | Bortezomib-loaded nanoparticles |
| KR102526793B1 (ko) * | 2021-11-03 | 2023-04-28 | 주식회사 에스엔바이오사이언스 | 입도분포 유지 안정성이 개선된 알부민 결합 탁산 나노입자 제조방법 |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US6749868B1 (en) * | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| IL141155A0 (en) * | 1998-07-30 | 2002-02-10 | Human Rt | Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin |
| JP4798832B2 (ja) * | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| KR20120053052A (ko) * | 2009-08-25 | 2012-05-24 | 아브락시스 바이오사이언스, 엘엘씨 | 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법 |
| CN104784121A (zh) * | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| WO2012092712A1 (zh) * | 2011-01-07 | 2012-07-12 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂 |
| CN102078306A (zh) * | 2011-01-11 | 2011-06-01 | 无锡圆容生物医药股份有限公司 | 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂 |
-
2013
- 2013-03-11 US US13/794,705 patent/US20140186447A1/en not_active Abandoned
- 2013-12-19 HK HK16104504.3A patent/HK1216611A1/zh unknown
- 2013-12-19 KR KR1020157020337A patent/KR20150100903A/ko not_active Withdrawn
- 2013-12-19 EP EP13868481.6A patent/EP2938340A4/en not_active Withdrawn
- 2013-12-19 SG SG11201505111TA patent/SG11201505111TA/en unknown
- 2013-12-19 NZ NZ630912A patent/NZ630912A/en unknown
- 2013-12-19 CN CN201380073926.7A patent/CN105007912A/zh active Pending
- 2013-12-19 RU RU2015131141A patent/RU2663687C2/ru active
- 2013-12-19 BR BR112015015319A patent/BR112015015319A2/pt not_active Application Discontinuation
- 2013-12-19 AU AU2013370955A patent/AU2013370955B2/en active Active
- 2013-12-19 CA CA2896288A patent/CA2896288A1/en not_active Abandoned
- 2013-12-19 JP JP2015550675A patent/JP2016504362A/ja active Pending
- 2013-12-19 MX MX2015008361A patent/MX2015008361A/es unknown
- 2013-12-19 WO PCT/US2013/076630 patent/WO2014105644A1/en not_active Ceased
-
2015
- 2015-06-23 IL IL239593A patent/IL239593A0/en unknown
- 2015-06-26 NI NI201500090A patent/NI201500090A/es unknown
- 2015-06-26 PH PH12015501486A patent/PH12015501486B1/en unknown
- 2015-07-02 ZA ZA2015/04762A patent/ZA201504762B/en unknown
- 2015-07-22 CR CR20150386A patent/CR20150386A/es unknown
-
2018
- 2018-02-23 JP JP2018030637A patent/JP2018087241A/ja active Pending
- 2018-10-25 US US16/170,522 patent/US20190192477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015131141A (ru) | 2017-02-03 |
| IL239593A0 (en) | 2015-08-31 |
| EP2938340A4 (en) | 2016-08-03 |
| WO2014105644A1 (en) | 2014-07-03 |
| JP2016504362A (ja) | 2016-02-12 |
| KR20150100903A (ko) | 2015-09-02 |
| AU2013370955B2 (en) | 2018-12-06 |
| RU2663687C2 (ru) | 2018-08-08 |
| EP2938340A1 (en) | 2015-11-04 |
| NI201500090A (es) | 2015-12-22 |
| ZA201504762B (en) | 2016-10-26 |
| JP2018087241A (ja) | 2018-06-07 |
| CA2896288A1 (en) | 2014-07-03 |
| US20140186447A1 (en) | 2014-07-03 |
| AU2013370955A1 (en) | 2015-07-16 |
| CN105007912A (zh) | 2015-10-28 |
| BR112015015319A2 (pt) | 2017-07-11 |
| NZ630912A (en) | 2017-05-26 |
| MX2015008361A (es) | 2016-03-11 |
| HK1216611A1 (zh) | 2016-11-25 |
| PH12015501486B1 (en) | 2020-12-16 |
| PH12015501486A1 (en) | 2015-09-21 |
| SG11201505111TA (en) | 2015-07-30 |
| US20190192477A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150386A (es) | Composiciones de nanoparticulas de albumina y paclitaxel | |
| CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| PE20151023A1 (es) | Triazolopirazinas | |
| CL2014001829A1 (es) | Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer. | |
| UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015003395A1 (es) | Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| DOP2015000157A (es) | Lactamas fusionadas de arilo y heteroarilo | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| CR20150326A (es) | Inhibidores de autotaxina | |
| EP2951739C0 (en) | VARIABLE DOSE DELIVERY OF DRUG | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CO7180225A2 (es) | Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafenib | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| ECSP14024526A (es) | Derivados bicíclicos de pirazinona | |
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| UY34776A (es) | Formulaciones de bromocriptina | |
| BR112014015753A8 (pt) | derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção | |
| CL2015001085A1 (es) | Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer. | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| MX359209B (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. |